Imidazo[4,5-b]pyridine-based AT1 / AT2 angiotensin II receptor antagonists

[1]  J. Prost,et al.  Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. , 1992, Hypertension.

[2]  J. Keiser,et al.  Renal hemodynamic and excretory responses to PD 123319 and losartan, nonpeptide AT1 and AT2 subtype-specific angiotensin II ligands. , 1992, The Journal of pharmacology and experimental therapeutics.

[3]  M. Galiñanes,et al.  PEG‐SOD and Myocardial Protection: Studies in the Blood‐ and Crystalloid‐Perfused Rabbit and Rat Hearts , 1992, Circulation.

[4]  W. Greenlee,et al.  In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[5]  W. Greenlee,et al.  In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[6]  Y. Christen,et al.  Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist , 1992, Clinical pharmacology and therapeutics.

[7]  C. J. Blankley,et al.  Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. , 1991, Journal of medicinal chemistry.

[8]  R. Chang,et al.  Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists. , 1991, Journal of medicinal chemistry.

[9]  Y. Christen,et al.  Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II , 1991, Circulation.

[10]  R. Chang,et al.  Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. , 1990, Molecular pharmacology.

[11]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.

[12]  S. Whitebread,et al.  Preliminary biochemical characterization of two angiotensin II receptor subtypes. , 1989, Biochemical and biophysical research communications.

[13]  J. Biollaz,et al.  Antihypertensive Therapy with MK 4211: Angiotensin II‐Renin Relationships to Evaluate Efficacy of Converting Enzyme Blockade , 1982, Journal of cardiovascular pharmacology.